 |
6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo-[1,2-alpha]pyrazin-8-amine bis-methanesulfonate |
|---|---|
| Trade Name | |
| Orphan Indication | Chronic lymphocytic leukemia |
| USA Market Approval | USA |
| USA Designation Date | 2014-04-14 00:00:00 |
| Sponsor | Gilead Sciences, Inc.;333 Lakeside Drive;Foster City, California, 94404 |
